Figure S3 from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

作者：Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu · 年份：2026 · DOI：10.1158/1535-7163.32713083 · 研究领域：Monoclonal and Polyclonal Antibodies Research、Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses

<p>Supplementary Fig.3. Characterization EMB-09, FIT1014-22a and FIT1014-23a. a EMB-09, FIT1014-22a, FIT1014-23a binding to human OX40 overexpressing CHO cells. b Cross binding of EMB-09, FIT1014-22a, FIT1014-23a to mouse OX40. Antibodies were captured by coated mouse OX40, and detection with HPR-labeled anti-hFc or anti-Rabbit Fc. c Cytokine release in PBMC. PBMC were treated with plate bounded antibodies for 48 hours, IL6 and TNFα were measured using LEGENDplex Human Inflammation Pannel 1 kit. d EMB-09 parental anti-OX40 mAb (44-16) blocks OX40/OX40L interaction. EMB-09 parental anti-OX40 mAb blocks OX40 ligand binding to CHO cells overexpressing OX40, tested by flow cytometry (left); EMB-09 parental anti-OX40 mAb (60 nM) blocks OX40 ligand mediated OX40 activation in Jurkat-OX40-NFκB reporter cells (right).</p>